Given their high target specificity and limited toxicity compared to small molecule drugs, biotherapeutics have revolutionized treatment paradigms across a myriad of clinical conditions, including metabolic disorders, cancers, neurological disorders and autoimmune disorders. In fact, the extent of growth of such therapies can be gauged from the fact that more than 300 biopharmaceuticals have been approved between 2002 and 2018. Such products are inherently complex, and their full potential continues to remain untapped owing to an array of concerns associated with their development, manufacturing and administration.
The recent surge in development of biologics has widened the opportunity for companies developing specific drug delivery technologies
Presently, over 80 technologies, with the potential to significantly improve drug properties and / or therapy adherence to various target drug classes, are under development
Proteins and peptides represent the dominant class of therapeutics using such technologies; although a number of novel delivery strategies are available, the parenteral route continues to be the preferred mode of delivery
Several stakeholders are engaged in the development of advanced technology platforms, capable of improving drug release properties and exploiting different invasive and non-invasive dosing strategies
The US is currently considered to be the base of operations for majority of the companies in this market, featuring a favorable research environment and a healthy mix of novice and well-established players
In order to achieve a competitive edge, technology developers are increasingly focusing on integration of advanced features in their respective drug delivery platforms and affiliated offerings
Over the years, more than 2,000 patents have been granted / filed related to delivery technologies for biologics, demonstrating continued efforts towards innovation in this domain
The increasing instances of partnerships showcase the rising interest in this domain; companies are actively collaborating to develop biologics with unique delivery mechanisms
Short term opportunity in this market is likely to be driven by licensing activity and will depend on the capability of novel technologies to meet unmet drug delivery needs
The major share is anticipated to remain within the developed regions, while the long term opportunity is likely to be driven by expansion into diverse therapeutic areas and exploiting different routes of delivery
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at email@example.com. Alternatively, you can place an Order by filling this Order Form.